Pancreatic Cancer Research

ResearcherUniversity of FloridaNo recent work listed

Matthew E. Merritt

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4617-9651; OpenAlex author ID A5001806074. Sources: OpenAlex.

Their work

Papers
2 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
5
Papers, trials and grants by year

2017: 2 papers

Papers 2

  1. Using a novel NQO1 bioactivatable drug, beta-lapachone (ARQ761), to enhance chemotherapeutic effects by metabolic modulation in pancreatic cancer. Co-author DOI 10.1002/jso.24624↗
  2. The NQO1 bioactivatable drug, β-lapachone, alters the redox state of NQO1+ pancreatic cancer cells, causing perturbation in central carbon metabolism. Last author DOI 10.1074/jbc.m117.813923↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Molly A. Silvers · 2 shared papers, 2017 · strength 0.13
  2. Muhammad Shaalan Beg · 2 shared papers, 2017 · strength 0.13
  3. David A. Boothman · 2 shared papers, 2017 · strength 0.13
  4. Xiumei Huang · 1 shared paper, 2017 · strength 0.06
  5. Daniel A. Laheru · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.